NClip

Topical Corticosteroids

3 min read

Topical Corticosteroids

Key Points

  • Topical corticosteroids reduce skin inflammation, pruritus, and erythema through local anti-inflammatory and immunosuppressive effects.
  • Potency ranges from low (hydrocortisone 1%) to super-high (clobetasol propionate), guided by condition severity and body location.
  • Prolonged use risks skin atrophy, striae, telangiectasia, and hypothalamic-pituitary-adrenal (HPA) axis suppression.
  • Thin-skinned areas (face, groin, axillae) require lower-potency agents to minimize adverse effects.

Mechanism of Action

Topical corticosteroids bind to intracellular glucocorticoid receptors in skin cells, inhibiting the release of inflammatory mediators (prostaglandins, leukotrienes, cytokines). This reduces vascular permeability, edema, erythema, and pruritus. They also suppress local immune cell activity, reducing the inflammatory cascade in dermatologic conditions.

Potency Classification

  • Low potency (Class VI-VII): Hydrocortisone 1 to 2.5% — safe for face, groin, and children.
  • Medium potency (Class III-V): Triamcinolone, betamethasone valerate — trunk and extremity use.
  • High potency (Class I-II): Clobetasol, halobetasol — thick plaques, palms, soles only.

Indications

  • Atopic dermatitis (eczema).
  • Contact dermatitis.
  • Psoriasis (localized plaques).
  • Seborrheic dermatitis.
  • Inflammatory skin conditions responsive to corticosteroid therapy.

Nursing Considerations

  • Match potency to body site: use lowest effective potency, especially on thin-skinned areas (face, intertriginous zones).
  • Apply a thin layer to affected areas only; do not apply to open wounds or infected skin unless combined with antimicrobial.
  • Assess skin integrity at each visit; monitor for signs of atrophy (thinning, shiny appearance, telangiectasia, striae).
  • Limit duration of high-potency agents to 2 weeks unless specifically directed; taper rather than abrupt discontinuation for prolonged use.
  • Do not occlude application sites with airtight dressings unless specifically prescribed (occlusion increases potency and absorption).
  • Monitor children closely; higher body-surface-area-to-weight ratio increases systemic absorption risk.
  • Assess for signs of HPA axis suppression with prolonged high-potency or widespread application.

Side Effects and Adverse Effects

  • Local: Skin atrophy, striae, telangiectasia, purpura, acneiform eruption, delayed wound healing.
  • Infection: Increased susceptibility to local skin infections; may mask infection signs.
  • Systemic (prolonged/high-potency/occlusive use): HPA axis suppression, Cushing syndrome features, hyperglycemia, growth retardation in children.
  • Withdrawal: Rebound flare if discontinued abruptly after prolonged use.

Health Teaching

  • Apply a thin layer only to affected areas; more is not better.
  • Do not use on the face or groin unless specifically prescribed by the provider.
  • Do not cover with occlusive dressings unless instructed.
  • Report skin thinning, stretch marks, persistent redness, or signs of infection.
  • Do not stop abruptly after prolonged use; follow the provider’s tapering plan.
  • Keep follow-up appointments to monitor skin condition and treatment response.

Self-Check

  1. Why should high-potency topical corticosteroids not be used on the face?
  2. What skin changes indicate prolonged topical corticosteroid overuse?
  3. Why is occlusive dressing application significant when using topical corticosteroids?

Graph View

Backlinks